Loxo Oncology, Inc. (NASDAQ:LOXO) has received an average recommendation of “Buy” from the eleven ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $92.00.

LOXO has been the topic of several recent research reports. JMP Securities lowered Loxo Oncology from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $83.12 to $17.14 in a research report on Tuesday, August 29th. They noted that the move was a valuation call. Morgan Stanley restated an “overweight” rating and set a $103.00 price target (up from $95.00) on shares of Loxo Oncology in a research report on Friday, October 6th. William Blair initiated coverage on Loxo Oncology in a research report on Tuesday, November 28th. They set an “outperform” rating on the stock. Citigroup reduced their price target on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Thursday, November 16th. Finally, Zacks Investment Research lowered Loxo Oncology from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.

Loxo Oncology (NASDAQ:LOXO) traded up $0.77 on Friday, reaching $80.91. The company had a trading volume of 238,493 shares, compared to its average volume of 376,780. Loxo Oncology has a fifty-two week low of $30.51 and a fifty-two week high of $95.92.

In other news, major shareholder Aisling Capital Iii Lp sold 500,000 shares of Loxo Oncology stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $75.00, for a total value of $37,500,000.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $86.52, for a total value of $133,327.32. Following the completion of the sale, the insider now owns 1,541 shares in the company, valued at $133,327.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,604,555 shares of company stock worth $123,763,042. Corporate insiders own 27.80% of the company’s stock.

Several hedge funds have recently modified their holdings of LOXO. Teachers Advisors LLC grew its position in shares of Loxo Oncology by 27.2% in the 1st quarter. Teachers Advisors LLC now owns 28,162 shares of the biopharmaceutical company’s stock worth $1,185,000 after buying an additional 6,023 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Loxo Oncology by 42.8% in the 1st quarter. Vanguard Group Inc. now owns 733,248 shares of the biopharmaceutical company’s stock valued at $30,856,000 after purchasing an additional 219,837 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in shares of Loxo Oncology by 70.4% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 73,892 shares of the biopharmaceutical company’s stock valued at $3,110,000 after purchasing an additional 30,533 shares during the period. Bank of America Corp DE lifted its stake in shares of Loxo Oncology by 162.6% in the 1st quarter. Bank of America Corp DE now owns 8,176 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 5,063 shares during the period. Finally, TD Asset Management Inc. purchased a new position in shares of Loxo Oncology in the 2nd quarter valued at approximately $779,000. Hedge funds and other institutional investors own 99.98% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/loxo-oncology-inc-loxo-receives-92-00-consensus-target-price-from-analysts/1775217.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Analyst Recommendations for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.